Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 107Gliosarcoma 48Glioma 41Brain Neoplasms 38Astrocytoma 38Central Nervous System Neoplasms 30Oligodendroglioma 27Medulloblastoma 15Melanoma 14Neuroblastoma 13Ependymoma 11Neoplasms 10Familial ependymoma 8Choroid Plexus Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Sarcoma 6Optic Nerve Glioma 6Neuroectodermal Tumors, Primitive 6Neoplasm Metastasis 6Sarcoma, Ewing 5Recurrence 5Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Lymphoma 4Glioma, Subependymal 4Spinal Cord Neoplasms 3Rhabdomyosarcoma 3Pinealoma 3

Interventions

lonafarnib 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Supratentorial Neoplasms × Temozolomide × Clear all
NCT00102648 2024-10-17

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
34 enrolled
CNSSarcoma

Glioblastoma, Supratentorial Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡